Sierra Bancorp Reports Strategic Securities Transaction as Well as Fourth Quarter and Year End 2023 Results
PORTERVILLE, Calif.–(BUSINESS WIRE)–Sierra Bancorp (Nasdaq: BSRR), parent of Bank of the Sierra, today announced a strategic securities transaction (“securities... Read more.
Leonardo DRS Schedules Fourth Quarter 2023 and Full Year 2023 Earnings Conference Call for February 27, 2024
ARLINGTON, Va.–(BUSINESS WIRE)–Leonardo DRS, Inc. (Nasdaq: DRS) has scheduled a conference call for Tuesday, February 27, 2024 beginning at 10:00 a.m.... Read more.
o9 Solutions Submitted and Validated Science-Based Emissions Reduction Targets
DALLAS–(BUSINESS WIRE)–o9 Solutions, a leading enterprise AI software platform provider for transforming planning and decision-making, today announced... Read more.
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
NATICK, Mass.–(BUSINESS WIRE)–$ALUR #Allurion—Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the... Read more.
Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market
Company’s second product to begin shipping to wholesale partners in January SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company... Read more.
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on net sales MENLO PARK, Calif.–(BUSINESS... Read more.
Littlejohn & Co. Announces Nine Promotions
GREENWICH, Conn.–(BUSINESS WIRE)–Littlejohn & Co. LLC (“Littlejohn”), a private investment firm based in Greenwich, CT, today announced that... Read more.
Elmhurst® 1925 Launches The First Ever Plant-Based Sour Cream In A Pouch
Dairy-free pioneer’s rich & creamy Sour Cream comes to Publix this Winter ELMA, N.Y.–(BUSINESS WIRE)–Elmhurst 1925, maker of simple, nutritious... Read more.
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated HOUSTON–(BUSINESS WIRE)–$KRBP #Celltherapy—Kiromic BioPharma,... Read more.
CORRECTING and REPLACING TD SYNNEX Announces Launch of Secondary Public Offering of Common Stock and Concurrent Share Repurchase
FREMONT, Calif. & CLEARWATER, Fla.–(BUSINESS WIRE)–First paragraph should read: TD SYNNEX Corporation (NYSE: SNX) (“TD SYNNEX” or the “Company”)... Read more.